AGN 205728 |
| Katalog-Nr.GC35268 |
AGN 205728 ist ein potenter und selektiver RARγ-Antagonist mit Ki/IC95-Werten von 3 nM/0,6 nM; keine Hemmung von RARα und RARβ.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 859498-05-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
AGN 205728 is a potent and selective RARγ antagonist with Ki/IC95 values of 3 nM/ 0.6 nM; no inhibiton on RARα and RARβ.IC50 value: 3 nM/ 0.6 nM(Ki/IC95)Target: RARγ antagonistMore information can be found in the following patent, Compound 7a.Preparation of disubstituted chalcone oximes having RARγ retinoid receptor antagonist activityBy Tsang, Kwok Yin; Sinha, Santosh; Liu, Xiaoxia; Bhat, Smita; Chandraratna, Roshantha A.From PCT Int. Appl. (2005), WO 2005066115 A2 20050721.
[1]. Tsang, Kwok Yin, et al. Preparation of disubstituted chalcone oximes having RARγ retinoid receptor antagonist activity. Appl. (2005), WO 2005066115 A2 20050721.
| Cas No. | 859498-05-8 | SDF | |
| Canonical SMILES | CC(C=C1)=CC=C1C2=CCC(C)(C)C3=C2C=CC(C(/C=C/C4=CC=C(C(O)=O)C=C4)=N/O)=C3 | ||
| Formula | C29H27NO3 | M.Wt | 437.53 |
| Löslichkeit | Soluble in DMSO | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.2856 mL | 11.4278 mL | 22.8556 mL |
| 5 mM | 0.4571 mL | 2.2856 mL | 4.5711 mL |
| 10 mM | 0.2286 mL | 1.1428 mL | 2.2856 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 10 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *